Literature DB >> 12270937

Role of TRAF3 and -6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor.

Suwan K Sinha1, Sunny Zachariah, Herson I Quiñones, Masahisa Shindo, Preet M Chaudhary.   

Abstract

X-linked ectodermal dysplasia receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to be highly expressed in ectodermal derivatives during embryonic development and binds to ectodysplasin-A2 (EDA-A2). By using a subclone of 293F cells with stable expression of XEDAR, we report that XEDAR activates the NF-kappaB and JNK pathways in an EDA-A2-dependent fashion. Treatment with EDA-A2 leads to the recruitment of TRAF3 and -6 to the aggregated XEDAR complex, suggesting a central role of these adaptors in the proximal aspect of XEDAR signaling. Whereas TRAF3 and -6, IKK1/IKKalpha, IKK2/IKKbeta, and NEMO/IKKgamma are involved in XEDAR-induced NF-kappaB activation, XEDAR-induced JNK activation seems to be mediated via a pathway dependent on TRAF3, TRAF6, and ASK1. Deletion and point mutagenesis studies delineate two distinct regions in the cytoplasmic domain of XEDAR, which are involved in binding to TRAF3 and -6, respectively, and play a major role in the activation of the NF-kappaB and JNK pathways. Taken together, our results establish a major role of TRAF3 and -6 in XEDAR signaling and in the process of ectodermal differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270937     DOI: 10.1074/jbc.M207923200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  EDA signaling and skin appendage development.

Authors:  Chang-Yi Cui; David Schlessinger
Journal:  Cell Cycle       Date:  2006-09-14       Impact factor: 4.534

Review 2.  Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.

Authors:  Joanne M Hildebrand; Zuoan Yi; Claire M Buchta; Jayakumar Poovassery; Laura L Stunz; Gail A Bishop
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

3.  Poor survival with wild-type TP53 ovarian cancer?

Authors:  Kwong-Kwok Wong; Daisy I Izaguirre; Suet-Yan Kwan; Erin R King; Michael T Deavers; Anil K Sood; Samuel C Mok; David M Gershenson
Journal:  Gynecol Oncol       Date:  2013-06-22       Impact factor: 5.482

4.  Enhanced Toll-like receptor (TLR) responses of TNFR-associated factor 3 (TRAF3)-deficient B lymphocytes.

Authors:  Ping Xie; Jayakumar Poovassery; Laura L Stunz; Sonja M Smith; Mark L Schultz; Lindsey E Carlin; Gail A Bishop
Journal:  J Leukoc Biol       Date:  2011-10-04       Impact factor: 4.962

Review 5.  Inactivation of X-linked tumor suppressor genes in human cancer.

Authors:  Runhua Liu; Mandy Kain; Lizhong Wang
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

6.  Macrophage-derived EDA-A2 inhibits intestinal stem cells by targeting miR-494/EDA2R/β-catenin signaling in mice.

Authors:  Lele Song; Renxu Chang; Xia Sun; Liying Lu; Han Gao; Huiying Lu; Ritian Lin; Xiaorong Xu; Zhanju Liu; Lixing Zhan
Journal:  Commun Biol       Date:  2021-02-16

7.  X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjögren's syndrome.

Authors:  Margherita Sisto; Loredana Lorusso; Sabrina Lisi
Journal:  Clin Exp Med       Date:  2015-12-11       Impact factor: 3.984

Review 8.  Multiple roles of TRAF3 signaling in lymphocyte function.

Authors:  Gail A Bishop; Ping Xie
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  EDA2R mediates podocyte injury in high glucose milieu.

Authors:  Xiqian Lan; Vinod Kumar; Alok Jha; Rukhsana Aslam; Haichao Wang; Kehong Chen; Yueming Yu; Weimei He; Feilan Chen; Huairong Luo; Ashwani Malhotra; Pravin C Singhal
Journal:  Biochimie       Date:  2020-04-15       Impact factor: 4.079

10.  Tumor Suppressor Gene XEDAR Promotes Differentiation and Suppresses Proliferation and Migration of Gastric Cancer Cells Through Upregulating the RELA/LXRα Axis and Deactivating the Wnt/β-Catenin Pathway.

Authors:  Xinwu Zhang; Di Zhang; Xiaoli Sun; Shunle Li; Yun Sun; Hongjun Zhai
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.